Research programme: dopamine D3 receptor antagonists - sanofi-aventis

Drug Profile

Research programme: dopamine D3 receptor antagonists - sanofi-aventis

Alternative Names: MDL 815541; MDL 815994

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Anxiety disorders; Drug abuse; Migraine; Schizophrenia

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 10 Apr 2003 Preclinical trials in Alzheimer's disease (unspecified route)
  • 10 Apr 2003 Preclinical trials in Drug abuse (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top